China Grants BioCurex's RECAF Patent: Largest Population Country In The World Approves Technology BioCurex Inc. (OTCBB:BOCX) is pleased to announce that a patent for its proprietary RECAF(TM) technology for cancer diagnosis has been approved and granted in the People's Republic of China. The patent covers the technologies used in the Company's Histo-RECAF(TM) and Cryo-RECAF(TM)
That is from Nov 2003.
BioCurex has already been issued patents in Australia and Russia and has patents pending in Canada and Japan and most European countries with pending approvals for diagnostic and therapeutic applications which have a much greater market share potential than already stated.
Patents relate to developing the method for diagnostic and treatment of cancer using a new cancer marker called "RECAF." These patents are presently registered in 24 countries with ongoing registrations currently being conducted. Patents are stated at cost and have a definite life.
Biocurex's technology is protected by a United States patent which expires in 2014 and by patents in Australia, Russia, and China which expire in 2015. Biocurex has also filed patent applications in Canada and six other foreign countries.
U.S. U.S.10/688,464 app, continuation of U.S. Patent 6,514,686 Russia 2161042 Patent Finland 970990 app (identified in Inpadoc as 9700990) Canada 2,197,490 app Norway 19971256 app EPO 95940906.1 app China 200310104769.x app (identified in Inpadoc as 1132012), continuation of Patent 95195125.4 (identified in Inpadoc as 1169778) Japan HEI. 8-510734 app (identified in Inpadoc as JP 11511847) Brazil PI 9508959-4 app Australia 2003204325 app (identified in Inpadoc as 9537648 A1), continuation of 714966 Patent